Minimally invasive skin sampling by microbiopsy
Microbiopsy engineered for minimally invasive and suture-free sub-millimetre skin sampling
This study introduces Prof Prow’s microbiopsy device,highlighting its effectiveness in obtaining small, high-quality skin samples for molecular analysis. The device provides a valuable, patient-friendly alternative for diagnosing neoplastic and inflammatory skin diseases without the need for local anesthesia.
Microbiopsy-based minimally invasive skin sampling for molecular analysis is acceptable to Epidermolysis Bullosa Simplex patients where conventional diagnostic biopsy was refused
This publication validates the use of the microbiopsy device in sensitive conditions such as epidermolysis bullosa simplex, where patients often refuse biopsies. This study underscores the device’s high patient acceptance and utility in molecular diagnostics, making it ideal for fragile skin conditions.
Microbiopsy biomarker profiling in a superficial melanoma resembling a pigmented basal cell carcinoma
This study investigated the application of the microbiopsy device in differentiating melanoma from basal cell carcinoma, a significant diagnostic challenge. The results highlight how minimally invasive sampling enables biomarker analysis for accurate and early skin cancer diagnosis.
Automated and advanced imaging for skin diagnostics
Automated segmentation of skin strata in reflectance confocal microscopy depth stacks
This study highlights Prof Prow’s contributions to automated reflectance confocal microscopy segmentation, presenting an algorithm to classify skin strata with precision. This automation supports rapid and consistent analysis of skin layers, advancing computer-aided diagnostics with real-time imaging integration.
Assessment of a diagnostic classification system for management of lesions to exclude melanoma
Prof Prow and Dr Yamada’s involvement in this study brought forward the MOLEM schema, a standardized classification for melanocytic lesions. This system aids machine learning algorithms, providing consistent criteria for training AI in melanoma diagnostics.
The experience of 3D total-body photography to monitor nevi: Results from an Australian general population-based cohort study
Prof Prow’s exploration of 3D total-body photography showcases its effectiveness as a non-invasive monitoring tool for skin lesions.The study’s results support the use of 3D imaging to reduce unnecessary biopsies and improve continuous monitoring in high-risk patients.
The fractional laser-induced coagulation zone characterized over time by laser scanning confocal microscopy—A proof of concept study
Prof Prow’s work with fractional laser-assisted imaging demonstrates how confocal microscopy can precisely monitor skin structures post-treatment. This approach validates using laser imaging for enhanced visualization of drug uptake zones, highlighting his contributions to in real-time monitoring technologies.
Nanoscale delivery systems to revolutionize skin health
High aspect ratio elongated microparticles for enhanced topical drug delivery in human volunteers
This foundational study introduces elongated microparticle (EMP) technology and demonstrates its ability to penetrate skin barriers effectively. EMPs provide targeted drug delivery directly to affected skin layers, supporting high-dose localized treatments for conditions such as hyperkeratotic lesions.
Using elongated microparticles to enhance tailorable nanoemulsion delivery in excised human skin and volunteers
This publication builds on Prof Prow and Dr Yamada’s EMP technology, integrating it with nanoemulsion formulations for enhanced penetration depth and sustained drug release in the skin. The findings highlight EMP’s compatibility with hydrophobic compounds, establishing a robust platform for targeted therapeutic applications.
Elongated microparticles tuned for targeting hyaluronic acid delivery to specific skin strata
In this study, Prof Prow and Dr Yamada further refine the EMP technology to target specific skin layers, demonstrating its adaptability for cosmeceutical and therapeutic applications. The controlled penetration depth ensures that active agents remain within the epidermal layers, maximizing treatment efficacy while minimizing side effects.
Translating skin technologies from concept to clinic
Nanoparticle enhanced blue light therapy
This study explores the use of nanoparticles to improve blue light therapy for antimicrobial and anticancer applications, demonstrating their potential to enhance treatment specificity and effectiveness. Prof Prow’s involvement highlights his commitment to sustainable, non-invasive skin therapies that reduce reliance on traditional antibiotics, thus supporting global efforts against antimicrobial resistance.
Electrochemical stability of PEDOT for wearable on-skin application
Prof Prow and Dr Yamada’s research into biocompatible, conducting polymers such as PEDOT showcases their dedication to developing sustainable materials for skin-attached diagnostics. This study on PEDOT’s stability in wearable applications reflects a focus on environmentally friendly and patient-safe materials for continuous health monitoring.
Health-related toxicity of emerging per- and polyfluoroalkyl substances: Comparison to legacy PFOS and PFOA
This review assesses the health impacts of per- and polyfluoroalkyl substances (PFAS) and highlights Prof Prow and Dr Yamada’s environmental focus, particularly on reducing toxic exposures from everyday products. This study contributes to a broader understanding of the risks posed by persistent chemicals and underscores Prof Prow and Dr Yamada’s commitment to safer, more sustainable options in dermatological products.
A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients
In this study, Prof Prow and Dr Yamada assess the tolerability of BLZ-100, a fluorescent imaging agent, for intraoperative use in skin cancer surgeries. The trial illustrates their dedication to translating promising diagnostics from the lab to the clinic, offering safer, accessible options for cancer patients while reducing the need for harmful radiation-based imaging.
